[go: up one dir, main page]

AU712907B2 - Method for treatment of cancer and infectious diseases and compositions useful in same - Google Patents

Method for treatment of cancer and infectious diseases and compositions useful in same Download PDF

Info

Publication number
AU712907B2
AU712907B2 AU69528/96A AU6952896A AU712907B2 AU 712907 B2 AU712907 B2 AU 712907B2 AU 69528/96 A AU69528/96 A AU 69528/96A AU 6952896 A AU6952896 A AU 6952896A AU 712907 B2 AU712907 B2 AU 712907B2
Authority
AU
Australia
Prior art keywords
cells
heat shock
shock protein
sequence
xdel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU69528/96A
Other versions
AU6952896A (en
Inventor
F. Ulrich Hartl
Mee H. Hoe
Alan Houghton
Mark Mayhew
James E. Rothman
Yoshizumi Takeuchi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memorial Sloan Kettering Cancer Center
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of AU6952896A publication Critical patent/AU6952896A/en
Application granted granted Critical
Publication of AU712907B2 publication Critical patent/AU712907B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6043—Heat shock proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/622—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier non-covalent binding
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/625—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier binding through the biotin-streptavidin system or similar
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/828—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Description

I I WO 97/06685 PCT/US96/13233
DESCRIPTION
METHOD FOR TREATMENT OF CANCER AND INFECTIOUS DISEASES AND COMPOSITIONS USEFUL IN SAME The invention described herein was made in the course of work under NIH Core Grant No. CA 08748. The United States government may have certain rights in this invention.
BACKGROUND OF THE INVENTION This application relates to the use of heat shock proteins and similar peptide-binding proteins to stimulate an immunological response against antigens, including cancer-related antigens, autoimmune antigens and infectious disease antigens, found in a mammalian host.
Heat shock proteins were originally observed to be expressed in increased amounts in mammalian cells which were exposed to sudden elevations of temperature, while the expression of most cellular proteins is significantly reduced. It has since been determined that such proteins are produced in response to various types of stress, including glucose deprivation. As used herein, the term "heat shock protein" will be used to encompass both proteins that are expressly labeled as such as well as other stress proteins, including homologs of such proteins that are expressed constitutively in the absence of stressful conditions). Examples of heat shock proteins include BiP (also referred to as grp78), hsp/hsc70, gp96 (grp94), hsp60, hsp40 and Heat shock proteins have the ability to bind other proteins in their non-native states, and in particular to bind nascent proteins emerging from the ribosomes or extruded into endoplasmic reticulum. Hendrick and Hartl, Ann. Rev. Biochem. 62: 349-384 (1993); Hartl, Nature 381: 571-580 (1996). Further, heat shock proteins have been shown to play an important role in the proper folding and assembly of proteins in the cytosol, endoplasmic reticulum WO 97/06685 PCT/US96/13233 2 and mitochondria; in view of this function, they are referred to as "molecular chaperones". Frydman et al., Nature 370: 111-117 (1994); Hendrick and Hartl., Ann. Rev.
Biochem. 62:349-384 (1993); Hartl., Nature 381:571-580 (1996).
For example, the protein BiP, a member of a class of heat shock proteins referred to as the hsp70 family, has been found to bind to newly synthesized, unfolded u immunoglobulin heavy chain prior to its assembly with light chain in the endoplasmic reticulum. Hendershot et al., J. Cell Biol. 104:761-767 (1987). Another heat shock protein, gp96, is a member of the hsp90 family of stress proteins which localize in the endoplasmic reticulum. Li and Srivastava, EMBO J. 12:3143-3151 (1993); Mazzarella and Green, J. Biol.
Chem. 262:8875-8883 (1987). It has been proposed that gp96 may assist in the assembly of multi-subunit proteins in the endoplasmic reticulum. Wiech et al., Nature 358:169-170 (1992).
It has been observed that heat shock proteins prepared from tumors in experimental animals were able to induce immune responses in a tumor-specific manner; that is to say, heat shock protein purified from a particular tumor could induce an immune response in an experimental animal which would inhibit the growth of the same tumor, but not other tumors. Srivastava and Maki, 1991, Curr. Topics Microbiol. 167: 109-123 (1991). The source of the tumorspecific immunogenicity has not been confirmed. Genes encoding heat shock proteins have not been found to exhibit tumor-specific DNA polymorphism. Srivastava and Udono, Curr.
Opin. Immunol. 6:728-732 (1994). High resolution gel electrophoresis has indicated that gp96 may be heterogeneous at the molecular level. Feldweg and Srivastava, Int. J. Cancer 63:310-314 (1995). Evidence suggests that the source of heterogeneity may be populations of small peptides adherent to the heat shock protein, which may number in the hundreds.
Id. It has been proposed that a wide diversity of peptides adherent to tumor-synthesized heat shock proteins may render such proteins capable of eliciting an immune response in \1 WO 97/06685 PCT/US96/13233 3 subjects having diverse HLA phenotypes, in contrast to more traditional immunogens which may be somewhat HLA-restricted in their efficacy. Id.
Lukacs et al., J. Exp. Med. 178: 343-348 (1993), have reported the transfection of tumor cells with a mycobacterial heat shock protein-encoding gene, and the observation that the transfected cells lose tumorigenicity and induce what appears to be T-cell mediated protection against tumors in mice immunized using the transfected cells.
Lukacs et al. suggest that the loss of tumorigenicity could result from the interaction of the heat shock protein with p53 via increased efficiency of chaperone activity to produce proper folding and conformation of otherwise ineffective p53 protein. They further suggest that the highly immunogenic nature of the 65 kD bacterial hsp enhances the recognition of other, tumor-associated antigen molecules.
It has been suggested in the literature that mycobacterial heat shock proteins may play a role in the onset of autoimmune diseases such a rheumatoid arthritis. Thus, the practical utility of such bacterial proteins in vaccines for the treatment of humans is questionable. It is an object of the present invention to provide vaccine compositions which can be used to stimulate an immune response to antigens, including tumor and infectious disease antigens, present in mammalian cells without the introduction of mycobacterial proteins.
SUMMARY OF THE INVENTION It has now been found that administration of expressible polynucleotides encoding eukaryotic heat shock proteins to mammalian cells leads to the stimulation of an immune response to antigens present in those cells. This makes it possible to stimulate an immune response to treat a subject's disease condition, including an immune response to a tumor or an infectious disease, without having to isolate or characterize an antigen associated with the disease.
Thus, the present invention provides a method for stimulating a therapeutic or prophylactic immune response in a mammalian subject by treating the subject or a group of cells from the subject with an expressible polynucleotide encoding a eukaryotic heat shock protein. The expressed heat shock protein may have the same structure as native heat shock proteins, or may be a modified form adapted to control the trafficking of the expressed heat shock protein within the cells.
The invention further provides a method for stimulating a therapeutic immune response in a subject in need of such treatment, comprising the step of introducing to the subject, or to a target group of cells from the subject, an expressible polynucleotide encoding a eukaryotic heat shock protein.
0 0 BRIEF DESCRIPTION OF THE DRAWINGS Figs. 1A-H show tumour formation in mice injected with CMS-5 sarcoma cells and CMS -5 sarcoma cells acutely transfected with BiP-expressing vectors; S•and a.
Gee* 15 Figs. 2A-F show tumour formation in mice injected with CMS-5 sarcoma cells and CMS-5 sarcoma cells stably transfected with BiP-expressing vectors.
DETAILED DESCRIPTION OF THE INVENTION o The present invention provides a method for inducing or enhancing an 20 immune response to an antigen present in a target group of cells without requiring prior identification, characterisation or isolation of the antigen. The method of the invention may be used to induce an immune response to the antigen in the case 0 where there is no existing detectable disease-related immune response prior to S-practicing the method, or to enhance the disease-related immune response to a greater level. Fur purposes of simplicity, the specification and claims of this application will use the term" stimulating an immune response" to encompass both inducing a new immune response and enhancing a pre-existing immune response.
Throughout the description and claims of this specification, the word "comprise" and variations of the word, such as "comprising" and "comprises", is not intended to exclude other additives, components, integers or steps.
r We have found that administration of expressible polynucleotides encoding z eukaryotic heat shock proteins to mammalian cells leads to the stimulation of an 4A immune response to antigens present in those cells. While we do not intend to be bound by any particular mechanism, the full potential of our observations is best understood in the context of two mechanistic models which explain the observations.
S@
So So o S
S
POT/US 96/13233 IPEA/US 03 OCT 1S7 The first mechanism is based on the fact that heat shock proteins like BiP and gp96 are normally localized in the endoplasmic reticulum and are known to bind peptides and proteins in this location, and the belief that such binding may be a step in the presentation of an antigen to the immune system. Increasing the concentration of one or more heat shock proteins resident in the endoplasmic reticulum may cause an improvement in the efficiency of this process, and thus an increased immune response to the antigens present in the transfected cells.
The second mechanism is based upon the understanding that heat shock proteins and other proteins secreted from the endoplasmic reticulum may be recaptured by receptors known as erd-2 (KDEL) receptors and returned to the endoplasmic reticulum. This recapture process requires the presence of a specific retention pequence on the heat shock protein such XDEL. XDEL is the single letter,aminoacid code for the amino acid sequence variable-Asp-Glu-Leu.
Specific carboxy-terminal retention sequences are KDEL (Lys- Asp-Glu-Leu) and HDEL (His-Asp-Glu-Leu). By eliminating this retention sequence in heat shock proteins which bind to antigens or by otherwise interfering with the ability of the erd-2 receptor to recapture these heat shock proteins, the amount of antigen-associated heat shock protein secreted by a cell and therefore accessible to the immune system can be increased.
In accordance with either of these mechanisms, the stimulation of the immune response which is observed when an expressible polynucleotide encoding a heat shock protein is expressed in the cell flows from an increase in the amount of antigen-associated heat shock protein. Thus, in accordance with one embodiment of the invention there is provided a method for stimulating an immune response to an antigen present in a target group of mammalian cells, comprising administering to the target group of cells a composition effective to increase the amount of antigen-associated heat shock protein present in the cells. This can be o accomplished in several ways.
WO 97/06685 PCT/US96/13233 -6- First, the amount of antigen-associated heat shock protein can be increased by administering a polynucleotide encoding a heat shock protein which is expressed to produce recombinant heat shock protein that is processed and transported within the cell in the same manner as wild-type heat shock protein.
Second, the amount of antigen-associated heat shock protein can be increased by administering an expressible polynucleotide encoding a heat shock protein in a modified form adapted to control the trafficking of the expressed heat shock protein within the cells. This would include alterations of heat shock protein which either facilitate its secretion from the cell or its localization and/or retention on the cell. For example, secretion may be facilitated by mutating or eliminating portions of the heat shock protein that serve to retain the heat shock protein in the cell (for example by deleting sequences recognized by the erd-2 receptor such as KDEL or a functionally equivalent sequence or by adding an agent that interferes with binding of heat shock protein to erd-2), or by supplying mutated non-heat shock proteins erd-2 mutants) that increase heat shock protein secretion. Alternatively localization and retention may be accomplished by increasing the number and/or strength of retention or retrieval signals (e.g.
increasing erd-2 levels) or my by adding to a heat shock protein, a membrane anchor containing additional retention or retrieval sequence as well as transmembrane and cytoplasmic domains KKXX at the C-terminal end, or XXRR at the N-terminal end or function equivalents thereof.) Third, the amount of an antigen-associated heat shock protein can be increased by administering an expressible polynucleotide encoding a peptide or peptide which competitively inhibits the interaction of heat shock proteins with cellular elements to modify the trafficking of those heat shock proteins within the cell.
POTIUS 96/13233 IPEAIUS 03 OCT 1997 7 Preparation of Expressible Polvnucleotides The construction of expressible polynucleotides for use in the three embodiments of the invention share many common elements and use generally well known techniques.
These techniques are set forth in numerous literature references known to persons skilled in the art and so will not be repeated exhaustively here.
Expressible polynucleotide encoding a heat shock protein which is expressed to produce recombinant heat shock protein that is processed and transported within the cell in the same manner as wild-type heat shock protein can be constructed by incorporating a cDNA encoding a wild-type heat shock protein or a modified heat shock protein that retains both its heat shock protein functionality and the XDEL retention sequence into a mammalian expression vector.
Genes for various mammalian heat shock proteins have been cloned and sequenced, including, but not limited to, gp96, human: Genebank Accession No. X15187; Maki et al., Proc.
Nat'1 Acad. Sci. 87: 5658-5562 (1990), mouse: Genebank Accession No. M16370; Srivastava et al., Proc. Nat'1 Acad.
Sci. 84:3807-3811 (1987)); BiP, mouse: Genebank Accession No. U16277; Haas et al., Proc. Nat'l Acad. Sci. U.S.A. 2250-2254 (1988), human: Genebank Accession No. M19645; Ting et al., DNA 7: 275-286 (1988); hsp70, mouse: Genebank Accession No. M35021; Hunt et al., Gene 87: 199-204 (1990), human: Genebank Accession No. M24743; Hunt et al., Proc.
Nat'l Acad. Sci. U.S.A. 82: 6455-6489 (1995); and human: Genebank Accession No. D49547; Ohtsuka Biochem Biophys. Res. Commun. 197: 235-240 (1993).
In general, any type of mammalian expression vector can be used, although those with the highest transfection and expression efficiencies are preferred to maximize the levels of expression. Specific types of vectors which can be employed include herpes simplex viral based vectors: pHSV1 (Geller et al. Proc. Natl. Acad. Sci 87:8950-8954 (1990)); recombinant retroviral vectors: MFG T (Jaffee et al. Cancer Res. 53:2221-2226 (1993)); Moloney- Ksed retroviral vectors: LN, LNSX, LNCX, LXSN (Miller and AaRfhlnfr ~UPF WO 97/06685 PCT/US96/13233 8 Rosman Biotechniques 7:980-989 (1989)); vaccinia viral vector: MVA (Sutter and Moss Proc. Natl. Acad. Sci.
89:10847-10851 (1992)); recombinant adenovirus vectors pJM17 (Ali et al Gene Therapy 1:367-384 (1994)), (Berkner K.
L. Biotechniques 6:616-624 1988); second generation adenovirus vector: DE1/DE4 adenoviral vectors (Wang and Finer Nature Medicine 2:714-716 (1996) and Adenoassociated viral vectors: AAV/Neo (Muro-Cacho et al. J.
Immunotherapy 11:231-237 (1992)). Specific suitable expression systems for this purpose include pCDNA3 (In- Vitrogen), plasmid AH5 (which contains the SV40 origin and the adenovirus major late promoter), pRC/CMV (In-Vitrogen), pCMU II (Paabo et al., EMBO J. 5: 1921-1927 (1986)), pZip- Neo SV (Cepko et al., Cell 37: 1053-1062 (1984)) and pSRa (DNAX, Palo Alto, CA).
Expressible polynucleotides encoding any of the various modified forms heat shock proteins described above are constructed using similar techniques. For example, heat shock proteins can be produced which are modified to delete or block the carboxy-terminal XDEL sequence. Such a heat shock protein is adapted to permit the heat shock protein to be secreted from the endoplasmic reticulum and to interfere with the return of the protein to the endoplasmic reticulum that is mediated by the erd-2 receptors because the signal peptide recognized by the erd-2 receptors is missing.
Proteins of this type are referred to in the specification and claims of this application as XDEL-negative heat shock proteins.
Expressible XDEL-negative polynucleotides can be constructed by deleting the nucleotides encoding the amino acid sequence XDEL at the carboxy-terminus of the heat shock protein. This can be accomplished by PCR amplification of the wild-type cDNA using a primer that hybridizes in the region immediately adjacent to the portion coding for the XDEL signal, combined with a restriction site to be used for cloning the product into a desired vector for expression of the modified heat shock protein in mammalian cells as described above.
PCT/US 9 6/113 2 3 3 IPENUS 03 OCT 1997 9 As an alternative to the use of expressible polynucleotides encoding deletion mutants of heat shock proteins, the method of the invention may also employ expressible polynucleotides which encode heat shock proteins in which the carboxy-terminal retention sequence XDEL is masked by the addition of additional amino acids to the carboxyterminal end. The masking amino acids can serve only the masking function, or can be derived from an infectious agent (for example E7/E6 from human papilloma virus) in which case the masking amino acids may also function as an antigen.
Addition of masking amino acids can be accomplished as described in Munro et al., Cell 48: 899-907 (1987) in which a mutant (SAGGL) having two amino acids added after the XDEL was prepared by cloning in appropriate restriction sites to permit substitution of a sequence including the additional bases, or by. PCR amplification of the heat shock protein using a primer that hybridizes with the bases encoding the XDEL retention sequence and which has additional bases encoding the added nucleotides inserted between the XDEL-encoding bases and the stop codon. The number of additional amino acids does not matter, so long as the added amino acids do not alter the function of the heat shock protein. The nucleotides encoding the masked heat shock protein are then introduced into a mammalian expression vector as described above.
Another method which may be used to increase the amount of antigen-associated heat shock protein in the cells is to modify cytosolic heat shock proteins with an aminoterminal signal which causes the protein to be taken up into the endoplasmic reticulum where it can gain access to the secretory pathway. Amino-terminal signals which can accomplish this function are described in the art, including for example in von Heijne, J. Mol. Biol. 184: 99-105 (1985).
These signals generally comprise a positively-charged amino acid or group of a few amino acids at the amino terminal end of the peptide, a hydrophobic core region and a third region Sgreater polarity than the hydrophobic region. Such itional signal sequences can be introduced using PCR with rrtn QWFPIFF PCT/US 96/13233 IPEAUS 03 OCT 1997 a modified primer that includes the bases for the desired amino-terminal amino acids. A representative cytosolic heat shock protein which might be modified in this manner is hsp The expressible polynucleotide used in the method of the present invention may also encode a peptide or protein that competitively inhibits the interaction of heat shock proteins with cellular elements to modify the trafficking of those heat shock proteins within the cell. In particular, the expressible polynucleotide may encode a peptide or protein that includes a carboxy-terminal XDEL retention sequence which will compete with heat shock proteins, including endogenous heat shock proteins, for binding to the erd-2 receptors. This competitive peptide may itself be a heat shock protein, for example BiP, that retains the XDEL retention sequence, or it may be some other peptide or protein with a carboxy-terminal XDEL sequence.
Administration of Expressible Polvnucleotides The resulting expressible polynucleotide is delivered into cells of the subject by ex vivo or in vivo methods, for example as part of a viral vector as described above, or as naked DNA. Suitable methods include injection directly into tissue and tumors, transfection using liposomes (Fraley et al, Nature 370: 111-117 (1980)), receptor-mediated endocytosis (Zatloukal, et al., Ann. N.Y.
Acad. Sci. 660: 136-153 (1992)), particle bombardmentmediated gene transfer (Eisenbraun et al., DNA Cell. Biol.
12: 791-797 (1993)) and transfection using peptide presenting bacteriophage. Barry et al. Nature Medicine 2: 299-305 (1996).
The expressible polynucleotide may be administered to a subject in need of treatment in order to obtain a therapeutic immune response. The term "therapeutic immune response", as used herein, refers to an increase in humoral and/or cellular immunity, as measured by standard ST techniques, which is directed toward an antigen associated 1 with the subject's disease condition. Preferably, but not by WO 97/06685 PCT/US96/13233 11 way of limitation, the induced level of humoral immunity directed toward the antigen is at least four-fold, and preferably at least 16-fold greater than the levels of the humoral immunity directed toward the antigen prior to the administration of the expressible polynucleotide of this invention to the subject. The immune response may also be measured qualitatively, by means of a suitable in vitro assay or in vivo, wherein an arrest in progression or a remission of neoplastic or infectious disease in the subject is considered to indicate the induction of a therapeutic immune response.
A further aspect of the invention is the administration of an expressible polynucleotide in combination with other forms of treatment including surgery, radiation therapy, and chemotherapy, to provide a vaccination against recurrence of cancer. By priming the immune system of subjects to recognize the cancer cells of their own cancers, the immune system will be more prepared to counter a subsequent regrowth, thus improving the prognosis for the subjects. This same type of vaccination can be used to improve a subject's resistance to recurrent diseases, including many parasitic and viral diseases. Thus, the expressible polynucleotides of the invention may be administered to stimulate a prophylactic immune response.
The term "prophylactic immune response", as used herein, refers to an increase in long term humoral and/or cellular immunity, as measured by standard techniques, which is directed toward an antigen associated with the subject's disease condition. In general, the prophylactic immune response is measured qualitatively, wherein a delay in the onset of recurring system is achieved.
The subject treated in the method of the invention may be a human or non-human subject.
In various embodiments of the invention, the polynucleotide may encode a heat shock protein derived from the same species or alternatively from a different species relative to the species of the subject.
1 PGT/US 96/13233 EA/US 03 OCT 1997 -12 The cells into which the expressible polynucleotide are introduced may be neoplastic cells or other cancer cells from the subject to be treated or vaccinated. In particular, the method of the invention is usefully applied to treat or vaccinate subjects suffering from cancer including solid tumors and neoplastic disease such as sarcoma, lymphoma, carcinoma, leukemia and melanoma. The method of the invention may also be utilized to stimulate an immune response to infectious diseases, including parasitic, fungal, yeast, bacterial, mycoplasmal and viral diseases, where a particular class of cells can be identified as harboring the infective entity. For example, but not by way of limitation, the cells treated may be infected with a human papilloma virus, a herpes virus such as herpes simplex or herpes zoster, a retrovirus such as human immunodeficiency virus 1 or 2, a hepatitis virus, an influenza virus, a rhinovirus, respiratory syncytial virus, cytomegalovirus, adenovirus, Mycoplasma pneumoniae, a bacterium of the genus Salmonella, Staphylococcus, Streptococcus, Enterococcus, Clostridium, Escherichia, Klebsiella, Vibrio, Mycobacterium, amoeba, a malarial parasite, Trypanosoma cruzi, etc. Thus, for example, in the case of human papilloma virus (HPV), the expressible polynucleotide could be introduced into epithelial cells infected with HPV from the subject to be treated.
The method of the invention can be practiced using various compositions. One such composition of matter is a recombinant vector comprising a promoter system effective to promote expression of the vector in mammalian cells; and a region encoding a XDEL-negative heat shock protein. The vector may be one in which the bases encoding a XDELretention sequence have been deleted from the region encoding the heat shock protein, or one in which additional bases have been added to the region encoding the heat shock protein to mask the XDEL-retention sequence in the expressed product. An exemplary vector would include gp96, preferably uman gp96, as the heat shock protein.
PCTUS 9 6 13233 PEANUS OCT 1997 13 A further composition of matter in accordance with the invention is a recombinant vector comprising a promoter system effective to promote expression of the vector in mammalian cells; and a region encoding a cytosolic heat shock protein such as hsp70 to which a signal comprising a positively-charged amino acid or group of a few amino acids at the amino terminal end of the peptide, a hydrophobic core region and a third region of greater polarity than the hydrophobic region is attached to promote uptake of the expressed cytosolic heat shock protein by the endoplasmic reticulum has been added.
The invention will now be further described by way of the following non-limiting examples.
EXAMPLE 1 PREPARATION OF XDEL DELETION MUTANTS The preparation of mammalian expression vectors encoding full-length and KDEL-deleted Drosophila BiP cDNAs (dBiP, also referred to a grp78) is described in Munro et al., Cell 48: 899-907 (1987). The expression vector encoding dBIP with a KDEL deletion (KDEL-deleted dBiP, SAGM2) has the KDEL retention sequence replaced with a c-myc sequence in a modified AHP2 plasmid. A further construct, WT dBiP (SAGMK1) has the c-myc sequence inserted between the KDEL retention sequence and the balance of the dBiP.
Wild type mouse BiP cDNA was cloned into plasmid pBSBiP. Haas, Proc. Nat'l Acad. Sci. USA 85: 2250-2254 (1988) In this plasmid, the BiP sequence is flanked by BamH I sites. The BamH I fragment was therefore recovered from pBSBiP and cloned into the BamH I site of mammalian expression vector pCDNA3 (In-Vitrogen). Mouse KDEL-deleted BiP was constructed using pCDNA3 by cloning the Bgl II-EcoR V PCR fragment (nucleotide 1360 to nucleotide 1981) of BiP using two oligonucleotide primers complementary to BiP. The nucleotides coding for the last four amino acids (KDEL) were omitted, and a stop codon and an EcoR V restriction site put T n its place.
WO 97/06685 PCT/US96/13233 14 EXAMPLE 2 PREPARATION OF TUMOR CELLS EXPRESSING BiP sarcoma cells, a methylocholanthrene-induced fibrosarcoma of BALB/c mouse origin, were adapted to culture and grown in DMEM medium (Gibco Life Technologies, Inc.) supplemented with 10% FCS. Sub-confluent monolayers (2 X 10 9 cells) were transfected with 2 ug of mammalian expression vector containing BiP or KDEL-deleted BiP using lipofectamine (Gibco) according to the manufacturer's directions.
Briefly, the expression vector and 6 ul of lipofectamine were diluted separately in 100 uL serum-free medium (OPTI- MEM® I Reduced Serum Medium, Gibco-BRL). The two solutions were then mixed and incubated at room temperature for minutes to allow formation of DNA-liposome complexes. 800 uL OPTI-MEM® was added to the complexes, mixed, and overlaid onto rinsed cells. After a 6 hour incubation at 37 0 C, 1 mL growth medium containing 20% FCS was added. Fresh medium was added to the cells 24 hours post-transfection.
Stable clones were selected by adding 800 ug/mL geneticin (Gibco-BRL) to the cells 72 hours later. The selection medium was changed every 3 days. Colonies of stably transfected cells were seen after 10 to 14 days.
Expression of BiP for each clone picked was assayed for by radiolabeling. Newly synthesized BiP was detectable by immunoprecipitation and gel electrophoresis.
Acutely (transiently) BiP expressing clones were trypsinized and used for animal injection 60 hours posttransfection.
EXAMPLE 3 VACCINATION WITH BiP EXPRESSING TUMOR CELLS Freshly prepared acutely transfected CMS-5 sarcoma cells prepared in accordance with Example 2 were prepared for use in vaccination of mice by trypsinization and then washing three times in PBS. 2 X 106 cells were injected intradermally into the abdomen of CB6F-1/J [Balb/c x C57BL/6 Fl] mice (Jackson Laboratories) and monitored for tumor growth over a 90 day period. The results are summarized in WO 97/06685 PCT/US96/13233 15 Table 1 and shown graphically in Figs. 1A-H. As shown, injection with the parental CMS-5 sarcoma cells, with mock transfected cells, and with cells transfected with KDELdeleted vectors led in all cases to the formation of tumors.
Tumors also developed in one control mouse where the cells were transfected with the vector only (no BiP). On the other hand, only one of six mice transfected with the complete wild-type drosophila BiP (including the c-myc) or wild-type mouse BiP developed tumors.
TABLE 1 Cell Line Number of Percent Tumor Free Tumor Free Mice per Survivals number of mice injected Parental CMS5 0/4 0% Mock Transfected 0/3 0% Vector Only 1/3 33% Mouse BiP wild type 2/3 66% Mouse BiP KDEL deleted 0/3 0% Drosophila BiP wild type 3/3 100% Drosophila BiP KDEL deleted 0/3 0% EXAMPLE 4 The experiment of Example 3 was repeated using larger groups of mice and using two different clones of stable mouse BiP-expressing transfected cells. As shown in Table 2 and Figs 2A-F, the results were essentially the same, with none of the mice injected with the vector expressing wild-type mouse BiP having any detected tumor formation.
WO 97/06685 PCT/US96/13233 16 TABLE 2 Cell Lines Number of Percent Tumor Free Tumor Free mice per Survivals number mice injected Parental CMS5 0/4 0% Vector Only 4/15 27% Mouse BiP wild type: clone 1 6/6 100% Mouse BiP wild type: clone 2 11/11 100% Mouse BiP KDEL deleted: clone 1 1/9 11% Mouse BiP KDEL deleted: clone 2 2/15 13% EXAMPLE Tumor-free mice that had been injected with the wild-type BiP expression vector in the experiment of Example 4 were rechallenged after an interval of two months by injection of 2 X 106 or 10 X 106 CMS-5 sarcoma cells into the left flank of each mouse. Unimmunized CB6F-1/J mice of the same age group that had not been previously immunized were injected at the same time with 2 X 106 CMS-5 sarcoma cells as controls. As shown in Table 3, none of the previously immunized mice developed detectable tumors, while all three of the control mice developed tumors and died.
TABLE 3 Rejected Tumor Number of Tumor Free Survivals Mice/Number of Mice Injected Mouse BiP wild type: 3/3 100% clone 1 3/3 100% Mouse BiP wild type: 5/5 100% clone 2 6/6 100% Control 0/3 0% WO 97/06685 PCT/US96/13233 17 EXAMPLE 6 CONSTRUCTION OF VECTOR EXPRESSING qp96 To create an expressible vector encoding gp96, the coding region of murine GP96 (mGP96) was digested with BamH I, blunted with Klenow and cloned into the mammalian expression vector pRC/CMV (In-Vitrogen) which has been digested with Xba I and also blunted with Klenow. The resulting plasmid, p96/CMV was then used as template for generating a fragment spanning nucleotides 1653 to 2482 that lacks the nucleotides encoding the amino acids KDEL. The primers used for amplification of this fragment were primer: GCGGATCCTAGTTTAGACCAGTATGTC [SEQ ID No. 1] 3' primer: CCGAATTCGGGCCCCAATTTACTCTGTAGATTCCTTTTCTGTTT [SEQ ID No. 2] The restrictions sites for BamH I in the 5'-primer and EcoR I and Sal I in the 3'-primer are shown in bold italics. A stop codon (shown underlined) is provided four nucleotides from the Sal I restriction site in the 3'-primer. The BamH I/EcoR I PCR fragment was subcloned into pBlueScript II (Stratagene) to further amplify the amount of DNA. The amplified DNA was then digested with PflM I and Apa I, gel purified and subcloned into p96/CMV to give pMS215 which codes for KDEL-deleted gp96.
EXAMPLE 7 VACCINATION WITH GP96 EXPRESSING VECTORS Plasmids encoding the wt mGp96 (pMS216) and KDEL deleted mGp96 (215) are transfected into CMS-5 sarcoma cells as described in Example 2. 86 h post transfection, the acutely transfected CMS-5 sarcoma cells are trypsinized, washed in PBS and prepared for use in vaccination of mice as described in Example 3.
Various publications are cited herein, the contents of which are hereby incorporated by reference in their entireties.
I
WO 97/06685 PCT/US96/13233 18 SEQUENCE LISTING GENERAL INFORMATION: APPLICANT: Sloan-Kettering Institute for Cancer Research ROTHMAN, James E.
HARTL, F. Ulrich HOE, Mee H.
HOUGHTON, Alan TAKEUCHI, Yoshizumi MAYHEW, Mark (ii) TITLE OF INVENTION: Method for Treatment of Cancer and Infectious Diseases and Compositions Useful in Same (iii) NUMBER OF SEQUENCES: 2 (iv) CORRESPONDENCE ADDRESS: ADDRESSEE: Oppedahl Larson STREET: 1992 Commerce Street Suite 309 CITY: Yorktown STATE: NY COUNTRY: US ZIP: 10598 COMPUTER READABLE FORM: MEDIUM TYPE: Diskette 3.5 inch, 1.44 Mb storage COMPUTER: IBM compatible OPERATING SYSTEM: MS DOS SOFTWARE: Word Perfect (vi) CURRENT APPLICATION DATA APPLICATION NUMBER: FILING DATE:
CLASSIFICATION:
(vii) PRIOR APPLICATION DATA: APPLICATION NUMBER: FILING DATE: (viii) ATTORNEY/AGENT INFORMATION NAME: Larson, Marina T.
REGISTRATION NUMBER: 32,038 REFERENCE/DOCKET NUMBER: MSK.P-018-WO (ix) TELECOMMUNICATION
INFORMATION:
TELEPHONE: (914) 245-3252 TELEFAX: (914) 962-4330
TELEX:
INFORMATION FOR SEQ ID NO: 1: SEQUENCE CHARACTERISTICS: LENGTH: 27 TYPE: nucleic acid STRANDEDNESSS: double TOPOLOGY: linear (ii) MOLECULE TYPE: Genomic DNA (iii) HYPOTHETICAL:no (iv) ANTI-SENSE: yes FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE: ORGANISM: mouse (ix) feature WO 97/06685 PCT/US96/13233 19 OTHER INFORMATION: amplification primer for gp96 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1: GCGGATCCTA GTTTAGACCA GTATGTC 27 INFORMATION FOR SEQ ID NO: 2: SEQUENCE CHARACTERISTICS: LENGTH: 44 TYPE: nucleic acid STRANDEDNESSS: double TOPOLOGY: linear (ii) MOLECULE TYPE: Genomic DNA (iii) HYPOTHETICAL:no (iv) ANTI-SENSE: no FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE: ORGANISM: mouse (ix) feature OTHER INFORMATION: amplification primer for gp96 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2: CCGAATTCGG GCCCCAATTT ACTCTGTAGA TTCCTTTTCT GTTT 44

Claims (24)

1. A method for stimulating a therapeutic immune response in a subject in need of such treatment, comprising the step of introducing to the subject, or to a target group of cells from the subject, an expressible polynucleotide encoding a eukaryotic heat shock protein.
2. A method for stimulating a prophylactic immune response against recurrence of a disease from which a subject is suffering, comprising administering to the subject, or to a target group of cells from the subject harbouring an antigen associated with the disease, an expressible polynucleotide encoding a eukaryotic heat shock protein.
4. The method according to claim 1 or 2, wherein the eukaryotic heat shock protein is a heat shock protein from which the carboxy-terminal XDEL retention sequence has been deleted. 6 20 5. The method according to claim 1 or 2, wherein the eukaryotic heat shock protein is an XDEL-negative heat shock protein in which the carboxy-terminal XDEL retention sequence has been masked. 4. The method according to claim 1 or 2, wherein the eukaryotic heat shocksible polynucleotide encodes a eukaryotic heat shock protein havingfrom which the carboxy-terminal XDEL retention sequene has beention sequence of the sequence XDEL.
7. The method according to claim 6, wherein the eukaryotic heat shock protein is BiP. Sprotein is a heat shock protein in which the carboxy-terminal XDEL retentiongp96. sequence has been masked. 6. The method according to claims 1 or 2, wherein the expressible polynucleotide encodes a eukaryotic heat shock protein having a carboxy- terminal retention sequence of the sequence XDEL. 7. The method according to claim 6, wherein the eukaryotic heat shock protein is BiP.
8. The method according to any one of claims 1 to 7, wherein the eukaryotic f heat shock protein is gp96. WO 97/06685 PCT/US96/13233 21 1
9. The method according to any of claims 1 to 8, 2 wherein the cells are cancer cells. 1
10. The method according to any of claims 1 to 8, 2 wherein the cells are neoplastic cells. 1
11. The method according to claim 10, wherein the 2 neoplastic cells are selected from among sarcoma cells, 3 lymphoma cells, leukemia cells, carcinoma cells and melanoma 4 cells. 1
12. The method according to any of claims 1 to 8, 2 wherein the cells are infected with a virus. 1
13. The method according to any of claims 1 to 8, 2 wherein the cells are infected with a parasite. 1
14. The method according to any of claims 1 to 8, 2 wherein the cells are infected with a mycoplasma. 1
15. The method according to any of claims 1 to 8, 2 wherein the cells are infected with a bacterium. 1
16. The method according to any of claims 1 to 8, 2 wherein the cells are infected with a fungus or yeast. 1
17. The method according to any of claim 1 to 16, 2 wherein the expressible polynucleotide is introduced into a 3 target group of cells ex vivo, and the target group of cells 4 are thereafter administered to the subject. 1
18. The method according to claim 17, wherein the 2 composition is administered by transfection in a liposome. 1
19. The method according to any of claim 1 to 18, 2 wherein the subject is a human. A recombinant vector comprising a promoter system effective to promote expression of the vector in mammalian cells; and a region encoding a cytosolic heat shock protein comprising an amino terminal signal sequence effective to promote the uptake of the expressed cytosolic heat shock protein by the endoplasmic reticulum and (ii) a carboxy- terminal retention sequence which has been added to promote retention of he heat shock protein in the endoplasmic reticulum.
21. The recombinant vector of claim 20, wherein the signal sequence comprises a positively charged N-terminal region, a hydrophobic core region and a third region of greater polarity than the hydrophobic region.
22. The recombinant vector according to claim 20 or 21, wherein the cytosolic S" heat shock protein is
23. A method for stimulating an immune response to an antigen present in the 15 target group of mammalian cells, comprising administering to the target group of cells an expressible polynucleotide, wherein the expression of the polynucleotide is effective to increase the amount of antigen-associated heat shock protein present in the cells.
24. The method according to claim 23, wherein the expressible polynucleotide 20 encodes a eukaryotic heat shock protein.
25. The method according to claim 23 or 24, wherein the expressible polynucleotide encodes a peptide having a retention sequence recognised by the erd-2 receptors.
26. The method according to claim 25, wherein the retention sequence is XDEL.
27. A method for stimulating a therapeutic immune response according to claim 1 substantially as hereinbefore described with reference to any one of examples 3 to 5, and 7.
28. A recombinant vector according to claim 20 substantially as hereinbefore described with reference to any one of examples 1 and 6.
AU69528/96A 1995-08-18 1996-08-16 Method for treatment of cancer and infectious diseases and compositions useful in same Ceased AU712907B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US247995P 1995-08-18 1995-08-18
US249095P 1995-08-18 1995-08-18
US60/002490 1995-08-18
US60/002479 1995-08-18
PCT/US1996/013233 WO1997006685A1 (en) 1995-08-18 1996-08-16 Method for treatment of cancer and infectious diseases and compositions useful in same

Publications (2)

Publication Number Publication Date
AU6952896A AU6952896A (en) 1997-03-12
AU712907B2 true AU712907B2 (en) 1999-11-18

Family

ID=26670443

Family Applications (3)

Application Number Title Priority Date Filing Date
AU69528/96A Ceased AU712907B2 (en) 1995-08-18 1996-08-16 Method for treatment of cancer and infectious diseases and compositions useful in same
AU68984/96A Ceased AU724399B2 (en) 1995-08-18 1996-08-16 Heat shock protein-based vaccines and immunotherapies
AU68493/96A Withdrawn AU6849396A (en) 1995-08-18 1996-08-16 Method for treatment of cancer and infectious diseases and compositions useful in same

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU68984/96A Ceased AU724399B2 (en) 1995-08-18 1996-08-16 Heat shock protein-based vaccines and immunotherapies
AU68493/96A Withdrawn AU6849396A (en) 1995-08-18 1996-08-16 Method for treatment of cancer and infectious diseases and compositions useful in same

Country Status (8)

Country Link
US (11) US6663868B1 (en)
EP (2) EP0888053A4 (en)
JP (2) JP2000508884A (en)
AU (3) AU712907B2 (en)
CA (2) CA2229595A1 (en)
HU (1) HUP9802819A2 (en)
IL (2) IL123218A0 (en)
WO (3) WO1997006828A1 (en)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994029459A1 (en) 1993-06-04 1994-12-22 Whitehead Institute For Biomedical Research Stress proteins and uses therefor
US5997873A (en) * 1994-01-13 1999-12-07 Mount Sinai School Of Medicine Of The City University Of New York Method of preparation of heat shock protein 70-peptide complexes
US5961979A (en) 1994-03-16 1999-10-05 Mount Sinai School Of Medicine Of The City University Of New York Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
US6719974B1 (en) 1995-08-18 2004-04-13 Sloan-Kettering Institute For Cancer Research Heat shock protein-based vaccines and immunotherapies
US6773707B1 (en) 1995-08-18 2004-08-10 Sloan-Kettering Institute For Cancer Research Heat shock protein-based vaccines and immunotherapies
AU712907B2 (en) 1995-08-18 1999-11-18 Sloan-Kettering Institute For Cancer Research Method for treatment of cancer and infectious diseases and compositions useful in same
US6761892B1 (en) 1995-08-18 2004-07-13 Sloan-Kettering Institute For Cancer Research Heat shock protein-based vaccines and immunotherapies
US6331299B1 (en) 1995-08-18 2001-12-18 Sloan-Kettering Institute For Cancer Research Method for treatment of cancer and infectious disease and compositions useful in same
US5935576A (en) * 1995-09-13 1999-08-10 Fordham University Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens
US5837251A (en) 1995-09-13 1998-11-17 Fordham University Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases
US5985270A (en) * 1995-09-13 1999-11-16 Fordham University Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes
US6130087A (en) * 1996-10-07 2000-10-10 Fordham University Methods for generating cytotoxic T cells in vitro
CA2272536A1 (en) * 1996-11-26 1998-06-04 Stressgen Biotechnologies Corp. Immune responses using compositions containing stress proteins
US7157089B1 (en) 1996-11-26 2007-01-02 Stressgen Biotechnologies Corporation Immune responses using compositions containing stress proteins
US5830464A (en) * 1997-02-07 1998-11-03 Fordham University Compositions and methods for the treatment and growth inhibition of cancer using heat shock/stress protein-peptide complexes in combination with adoptive immunotherapy
US6017540A (en) 1997-02-07 2000-01-25 Fordham University Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes
CA2282426A1 (en) * 1997-02-18 1998-08-20 The Whitehead Institute For Biomedical Research Use of heat shock proteins to deliver moieties into cells
BE1011033A6 (en) * 1997-03-05 1999-04-06 Univ Bruxelles PHARMACEUTICAL AND / OR FOOD COMPOSITION FOR THE TREATMENT OF CONDITIONS RELATED TO A GRAFT REJECTION, AN ALLERGIC OR AUTOIMMUNE REACTION OR CANCER.
US6709672B2 (en) 1997-03-05 2004-03-23 Biotech Tools S.A. Pharmaceutical or food composition for treating pathologies associated with graft rejection or an allergic or autoimmune reaction
DK1336621T3 (en) * 1997-08-05 2006-07-31 Stressgen Biotechnologies Corp Immune response to HPV antigens induced by compositions comprising an HPV antigen and a stress protein or expression vector capable of expressing these proteins
CN100489105C (en) 1997-08-05 2009-05-20 恩温塔生物制药学公司 Immune response against HPV antigens elicited by compositions comprising HPV antigens and stress proteins or expression vectors thereof
AU779770B2 (en) * 1997-08-05 2005-02-10 Nventa Biopharmaceuticals Corporation Immune responses against HPV antigens elicited by compositions comprising an HPV antigen and a stress protein or an expression vector capable of expression of these proteins
AU2005201826B2 (en) * 1997-08-05 2008-01-17 Nventa Biopharmaceuticals Corporation Immune responses against HPV antigens elicited by compositions comprising an HPV antigen and a stress protein or an expression vector capable of expression of these proteins
WO1999022761A1 (en) * 1997-10-31 1999-05-14 Sloan-Kettering Institute For Cancer Research Conjugate heat shock protein-binding peptides
AU1045199A (en) * 1997-11-05 1999-05-24 Isis Innovation Limited Cancer gene
US5948646A (en) 1997-12-11 1999-09-07 Fordham University Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes
ES2285832T3 (en) 1998-02-20 2007-11-16 Univ Miami ANTIGENIC-PROTEIN PEPTIDE COMPLEX OF MODIFIED THERMAL SHOCK.
WO1999064583A2 (en) * 1998-06-12 1999-12-16 The Government Of The United States Of America, Represented By The Secretary, Department Of Healt H And Human Services Compositions and methods for modulating proteolytic degradation of intracellular targets
US6160088A (en) * 1998-07-29 2000-12-12 Sloan-Kettering Institute For Cancer KDEL receptor inhibitors
US6451316B1 (en) 1998-10-05 2002-09-17 University Of Conneticut Health Center Methods for generating antigen-reactive T cells in vitro
US6497880B1 (en) 1998-12-08 2002-12-24 Stressgen Biotechnologies Corporation Heat shock genes and proteins from Neisseria meningitidis, Candida glabrata and Aspergillus fumigatus
AU5926700A (en) 1999-07-08 2001-01-30 Stressgen Biotechnologies Corporation Induction of a th1-like response in vitro
AUPQ233799A0 (en) 1999-08-19 1999-09-09 Minister For Agriculture, Minister For Land And Water Conservation For And On Behalf Of The State Of New South Wales Recombinant sub-unit vaccine
GB9919733D0 (en) * 1999-08-19 1999-10-20 Colaco Camilo Vaccines against intracellular pathogens
EP1216055A2 (en) 1999-09-30 2002-06-26 Corixa Corporation Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
US7378096B2 (en) 1999-09-30 2008-05-27 Health Research, Inc. Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
US8128922B2 (en) 1999-10-20 2012-03-06 Johns Hopkins University Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen
US7030228B1 (en) 1999-11-15 2006-04-18 Miltenyi Biotec Gmbh Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby
GB9930443D0 (en) 1999-12-22 2000-02-16 King S College London Novel use of heat shock proteins
ATE438408T1 (en) 2000-01-14 2009-08-15 Whitehead Biomedical Inst INDUCTION OF CYTOTOXIC LYMPHOCYTES BY HEAT SHOCK PROTEIN FUSION PROTEINS DEPENDS ON THE ATP BINDING DOMAIN IN HSP AND IS CD4+ INDEPENDENT
AU2001267349A1 (en) * 2000-04-14 2001-10-30 Cistem Biotechnologies Gmbh Pharmaceutical preparations comprising modified peptides
AU5708601A (en) * 2000-04-17 2001-10-30 James E Rothman Javelinization of protein antigens to heat shock proteins
AU2001266694C1 (en) 2000-06-02 2005-09-01 University Of Connecticut Health Center Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy
SK18362002A3 (en) 2000-06-26 2004-02-03 Stressgen Biotechnologies Corporation Use of composition containing a fusion protein
ES2454640T3 (en) 2000-08-03 2014-04-11 Johns Hopkins University Molecular vaccine that carries a chaperone polypeptide from the endoplasmic reticulum to an antigen
NZ521694A (en) 2002-09-30 2005-05-27 Co2 Pac Ltd Container structure for removal of vacuum pressure
US7132109B1 (en) 2000-10-20 2006-11-07 University Of Connecticut Health Center Using heat shock proteins to increase immune response
CA2437503A1 (en) 2001-02-05 2002-08-15 Stressgen Biotechnologies Corp. Hepatitis b virus treatment
GB0106161D0 (en) * 2001-03-13 2001-05-02 King S College London Immunomodulators
US20040043419A1 (en) * 2001-04-17 2004-03-04 Rothman James E. Javelinization of protein antigens to heat shock proteins
IL160511A0 (en) 2001-08-20 2004-07-25 Univ Connecticut Health Ct Methods for preparing compositions comprising heat shock proteins or alpha-2-macroglobulin useful for the treatment of cancer and infectious disease
CN1304559C (en) * 2001-10-09 2007-03-14 杭州康科生物技术有限公司 Oncolytic microorganism expressing heat shock protein and its application
AU2003231098A1 (en) 2002-04-25 2003-11-10 University Of Connecticut Health Center Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
US6984389B2 (en) 2002-04-25 2006-01-10 University Of Connecticut Health Center Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
DE60323682D1 (en) * 2003-01-03 2008-10-30 Aurelium Biopharma Inc DIAGNOSTICS AND THERAPEUTIC APPLICATIONS FIXED ON HSC70 FOR ONE AGAINST MULTIPLE DRUGS RESISTANT TUMOR DISEASE
US7420037B2 (en) * 2003-02-13 2008-09-02 Antigenics Inc. Heat shock protein-based vaccines and immunotherapies
GB0303507D0 (en) * 2003-02-14 2003-03-19 Novartis Ag Organic compounds
US7309491B2 (en) 2003-04-11 2007-12-18 Antigenics Inc. Heat shock protein-based vaccines and immunotherapies
CA2521809A1 (en) * 2003-04-11 2004-10-28 Antigenics Inc. Improved heat shock protein-based vaccines and immunotherapies
WO2004096859A1 (en) * 2003-04-28 2004-11-11 Sekisui Chemical Co., Ltd. Chaperonine-target protein complex, method of producing the same, method of stabilizing target protein, method of immobilizing target protein, method of analyzing the structure of target protein, sustained-release preparation and method of producing antibody against target protein
WO2004098526A2 (en) 2003-05-05 2004-11-18 Johns Hopkins University Anti-cancer dna vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein
DK1625148T3 (en) 2003-05-21 2013-01-14 Biotech Tools Sa peptide Complex
EP2316844A3 (en) * 2003-05-21 2011-07-20 Biotech Tools S.A. Peptide complex
EP1479689A1 (en) * 2003-05-21 2004-11-24 Biotech Tools S.A. Peptide complex
WO2005028496A2 (en) 2003-09-12 2005-03-31 Antigenics, Inc. Vaccine for treatment and prevention of herpes simplex virus infection
EP1531160B1 (en) * 2003-11-12 2010-12-29 Alfa Biogene International B.V. Recovery of a heat shock protein
US20050191294A1 (en) * 2003-12-31 2005-09-01 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy
US7449196B2 (en) * 2004-07-09 2008-11-11 Robert Sabin Anti tumor compositions and methods of use
US20060120995A1 (en) * 2004-12-02 2006-06-08 Shah Maulik R Neoadjuvant genetic compositions and methods
CA2594040A1 (en) 2005-01-06 2006-07-13 The Johns Hopkins University Rna interference that blocks expression of pro-apoptotic proteins potentiates immunity induced by dna and transfected dendritic cell vaccines
US20070098735A1 (en) * 2005-10-29 2007-05-03 Chandawarkar Rajiv Y Methods for the Elimination of Pathogens and Other Particulate Agents
WO2007116409A2 (en) 2006-04-11 2007-10-18 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Improved vaccines comprising multimeric hsp60 peptide carriers
US20080081051A1 (en) * 2006-09-28 2008-04-03 Robert Sabin Method of manufacturing anti-tumor and anti-viral compositions
US9085638B2 (en) 2007-03-07 2015-07-21 The Johns Hopkins University DNA vaccine enhancement with MHC class II activators
WO2008124483A1 (en) * 2007-04-04 2008-10-16 Specigen, Inc. Protein cage immunotherapeutics
AU2009223838B2 (en) 2008-03-03 2012-07-26 The University Of Miami Allogeneic cancer cell-based immunotherapy
WO2009117116A2 (en) 2008-03-20 2009-09-24 University Of Miami Heat shock protein gp96 vaccination and methods of using same
US9527906B2 (en) 2008-04-18 2016-12-27 The General Hospital Corporation Immunotherapies employing self-assembling vaccines
CN102223894A (en) * 2008-11-21 2011-10-19 迈阿密大学 Hiv/siv vaccines for the generation of mucosal and systemic immunity
EP2270124A1 (en) * 2009-06-30 2011-01-05 The Procter & Gamble Company Bleaching compositions comprising a perfume delivery system
US9822154B2 (en) 2012-12-14 2017-11-21 Virginia Commonwealth University Immune modulator for immunotherapy and vaccine formulation
FR3011850B1 (en) * 2013-10-15 2018-04-06 Cfl Biotech THERAPEUTIC VACCINE AGAINST CANCER BASED ON IMMUNOGENIC STRESS PROTEINS
US10046047B2 (en) 2015-02-06 2018-08-14 Heat Biologics, Inc. Vector co-expressing vaccine and costimulatory molecules
AU2016260540B2 (en) 2015-05-13 2021-01-07 Agenus Inc. Vaccines for treatment and prevention of cancer
US20170260286A1 (en) 2016-03-10 2017-09-14 The General Hospital Corporation Antigen-Binding Fusion Proteins with Modified HSP70 Domains
CA3040123A1 (en) 2016-10-11 2018-04-19 University Of Miami Vectors and vaccine cells for immunity against zika virus
WO2018187260A1 (en) 2017-04-04 2018-10-11 Heat Biologics, Inc. Intratumoral vaccination
KR20210005646A (en) 2018-04-26 2021-01-14 아게누스 인코포레이티드 Heat shock protein-binding peptide composition and method for use thereof
WO2020231788A1 (en) * 2019-05-10 2020-11-19 Academia Sinica A vaccine comprising a nanoparticle encapsulating epitopes and adjuvant for neutraliying virus infection
WO2022047248A1 (en) * 2020-08-28 2022-03-03 Torigen Pharmaceuticals, Inc. Immune memory enhanced preparations and uses thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8727030D0 (en) * 1987-11-18 1987-12-23 Imp Cancer Res Tech Production of monoclonal antibodies
WO1994029459A1 (en) * 1993-06-04 1994-12-22 Whitehead Institute For Biomedical Research Stress proteins and uses therefor
US5348945A (en) 1990-04-06 1994-09-20 Wake Forest University Method of treatment with hsp70
IL99821A (en) * 1991-10-22 1996-07-23 Yeda Res & Dev Antitumor vaccines comprising cells transfected with a gene encoding human il-6
IT1262896B (en) * 1992-03-06 1996-07-22 CONJUGATE COMPOUNDS FORMED FROM HEAT SHOCK PROTEIN (HSP) AND OLIGO-POLY-SACCHARIDES, THEIR USE FOR THE PRODUCTION OF VACCINES.
GB9223816D0 (en) * 1992-11-13 1993-01-06 Medical Res Council Heat shock proteins and the treatment of tumours
US5997873A (en) * 1994-01-13 1999-12-07 Mount Sinai School Of Medicine Of The City University Of New York Method of preparation of heat shock protein 70-peptide complexes
US5750119A (en) 1994-01-13 1998-05-12 Mount Sinai School Of Medicine Of The City University Of New York Immunotherapeutic stress protein-peptide complexes against cancer
US5961979A (en) 1994-03-16 1999-10-05 Mount Sinai School Of Medicine Of The City University Of New York Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
US5541109A (en) 1994-04-19 1996-07-30 Rhone-Poulenc Rorer Pharmaceuticals Inc. Expression cloning of c-src SH3-domain binding proteins
AUPN461695A0 (en) 1995-08-07 1995-08-31 Technological Resources Pty Limited A process for reducing iron oxides
AU712907B2 (en) 1995-08-18 1999-11-18 Sloan-Kettering Institute For Cancer Research Method for treatment of cancer and infectious diseases and compositions useful in same
US5985270A (en) 1995-09-13 1999-11-16 Fordham University Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes
US5935576A (en) 1995-09-13 1999-08-10 Fordham University Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens
JPH11513369A (en) 1995-09-13 1999-11-16 フォーダム ユニバーシティー Treatment and prevention methods using heat shock proteins
US5837251A (en) 1995-09-13 1998-11-17 Fordham University Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases
WO1997026910A2 (en) 1996-01-27 1997-07-31 Max-Delbrück-Centrum für Molekulare Medizin Tumour vaccine for immunotherapy of malignant tumours
CA2272536A1 (en) 1996-11-26 1998-06-04 Stressgen Biotechnologies Corp. Immune responses using compositions containing stress proteins
US6017540A (en) 1997-02-07 2000-01-25 Fordham University Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes
CA2282426A1 (en) 1997-02-18 1998-08-20 The Whitehead Institute For Biomedical Research Use of heat shock proteins to deliver moieties into cells
US6075358A (en) 1998-01-09 2000-06-13 Siemens Aktiengesellschaft Device in a semiconductor manufacturing installation in particular for integrated circuits
ES2285832T3 (en) 1998-02-20 2007-11-16 Univ Miami ANTIGENIC-PROTEIN PEPTIDE COMPLEX OF MODIFIED THERMAL SHOCK.

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SATO ET AL, PROC. ANNU. AM. ASSOC. CANCER REASEARCH. 1994, VOL 35, PAGE A 2959 *

Also Published As

Publication number Publication date
US6641812B2 (en) 2003-11-04
US6656679B2 (en) 2003-12-02
US6605464B1 (en) 2003-08-12
WO1997006821A1 (en) 1997-02-27
WO1997006828A1 (en) 1997-02-27
US6663868B1 (en) 2003-12-16
US20030185842A1 (en) 2003-10-02
AU6849396A (en) 1997-03-12
US20040071721A1 (en) 2004-04-15
HUP9802819A2 (en) 1999-03-29
US20030082198A1 (en) 2003-05-01
JP2000507083A (en) 2000-06-13
JP4163253B2 (en) 2008-10-08
JP2000508884A (en) 2000-07-18
CA2229595A1 (en) 1997-02-27
AU6898496A (en) 1997-03-12
US20040071725A1 (en) 2004-04-15
US20040071724A1 (en) 2004-04-15
CA2229543A1 (en) 1997-02-27
US20040071720A1 (en) 2004-04-15
AU724399B2 (en) 2000-09-21
EP0888053A1 (en) 1999-01-07
EP0888053A4 (en) 2002-07-31
US20030021794A1 (en) 2003-01-30
WO1997006685A1 (en) 1997-02-27
US20030082197A1 (en) 2003-05-01
IL123218A0 (en) 1998-09-24
US20020198166A1 (en) 2002-12-26
IL123219A0 (en) 1998-09-24
EP0851764A4 (en) 2002-08-07
EP0851764A1 (en) 1998-07-08
US6673348B2 (en) 2004-01-06
AU6952896A (en) 1997-03-12

Similar Documents

Publication Publication Date Title
AU712907B2 (en) Method for treatment of cancer and infectious diseases and compositions useful in same
US6331299B1 (en) Method for treatment of cancer and infectious disease and compositions useful in same
US5861381A (en) Pharmaceutical composition for the treatment of a malignant tumor
AU766403B2 (en) Treatment of cervical cancer
Leifert et al. “Translocatory proteins” and “protein transduction domains”: a critical analysis of their biological effects and the underlying mechanisms
CA2143308A1 (en) Translocation signal facilitated nuclear delivery of macromolecules
CA2674552A1 (en) Vaccine
CN113061168B (en) Truncated fever with thrombocytopenia syndrome virus Gn protein and application thereof
US20040110928A1 (en) Peptide conjugates for drug delivery
US8258261B2 (en) Induction of tumor immunity by variants of folate binding protein
JP2003533445A (en) Javelinization of protein antigens against heat shock proteins
WO2023051701A1 (en) Mrna, protein and vaccine against sars-cov-2 infection
KR20040083429A (en) Biomolecule transduction motif mph-1-btm and the use thereof
AU2017229991A1 (en) Antigen-binding fusion proteins with modified HSP70 domains
JP4138073B2 (en) Human cancer regression antigen protein
EP1240317B1 (en) Nucleic acid vaccination
Perkins et al. VP22 enhances antibody responses from DNA vaccines but not by intercellular spread
US20040138115A1 (en) Local pain-combating agent
WO2023138333A1 (en) Recombinant sars-cov-2 protein vaccine, and preparation method therefor and use thereof
JP2003526323A (en) KDEL receptor inhibitor
JPH05103666A (en) Method for manifesting human nerve growth factor
CN117487828B (en) Nucleic acid molecules, fusion proteins and mRNA vaccines that recruit ligands to enhance antigen presentation
JP2000116383A (en) Human cancer regression antigen protein
AU2014274586B2 (en) Nucleic acids and proteins from streptococcus groups A & B
JPWO2005090576A1 (en) DNA construct for prevention of pertussis infection

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)